Report cover image

Global Medicines for Alzheimer Disease Treatment Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 101 Pages
SKU # APRC20354012

Description

Summary

According to APO Research, The global Medicines for Alzheimer Disease Treatment market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Medicines for Alzheimer Disease Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Medicines for Alzheimer Disease Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Medicines for Alzheimer Disease Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Medicines for Alzheimer Disease Treatment include Novartis AG, AbbVie Inc, Lupin Pharmaceuticals, Inc, Janssen Global Services, LLC, H. Lundbeck A/S, F. Hoffmann-La Roche Ltd, Daiichi Sankyo Company Limited, Amneal Pharmaceuticals LLC and Actiza Pharmaceutical Private Limited, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Medicines for Alzheimer Disease Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Medicines for Alzheimer Disease Treatment.

The Medicines for Alzheimer Disease Treatment market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Medicines for Alzheimer Disease Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Medicines for Alzheimer Disease Treatment Segment by Company

Novartis AG
AbbVie Inc
Lupin Pharmaceuticals, Inc
Janssen Global Services, LLC
H. Lundbeck A/S
F. Hoffmann-La Roche Ltd
Daiichi Sankyo Company Limited
Amneal Pharmaceuticals LLC
Actiza Pharmaceutical Private Limited
AC Immune

Medicines for Alzheimer Disease Treatment Segment by Type

NMDA Receptor Antagonists
Cholinesterase Inhibitors

Medicines for Alzheimer Disease Treatment Segment by Application

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Medicines for Alzheimer Disease Treatment Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medicines for Alzheimer Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Medicines for Alzheimer Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medicines for Alzheimer Disease Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Medicines for Alzheimer Disease Treatment manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Medicines for Alzheimer Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Table of Contents

101 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Medicines for Alzheimer Disease Treatment Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Medicines for Alzheimer Disease Treatment Sales Estimates and Forecasts (2020-2031)
1.3 Medicines for Alzheimer Disease Treatment Market by Type
1.3.1 NMDA Receptor Antagonists
1.3.2 Cholinesterase Inhibitors
1.4 Global Medicines for Alzheimer Disease Treatment Market Size by Type
1.4.1 Global Medicines for Alzheimer Disease Treatment Market Size Overview by Type (2020-2031)
1.4.2 Global Medicines for Alzheimer Disease Treatment Historic Market Size Review by Type (2020-2025)
1.4.3 Global Medicines for Alzheimer Disease Treatment Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Medicines for Alzheimer Disease Treatment Sales Breakdown by Type (2020-2025)
1.5.2 Europe Medicines for Alzheimer Disease Treatment Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Medicines for Alzheimer Disease Treatment Sales Breakdown by Type (2020-2025)
1.5.4 South America Medicines for Alzheimer Disease Treatment Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Medicines for Alzheimer Disease Treatment Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Medicines for Alzheimer Disease Treatment Industry Trends
2.2 Medicines for Alzheimer Disease Treatment Industry Drivers
2.3 Medicines for Alzheimer Disease Treatment Industry Opportunities and Challenges
2.4 Medicines for Alzheimer Disease Treatment Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Medicines for Alzheimer Disease Treatment Revenue (2020-2025)
3.2 Global Top Players by Medicines for Alzheimer Disease Treatment Sales (2020-2025)
3.3 Global Top Players by Medicines for Alzheimer Disease Treatment Price (2020-2025)
3.4 Global Medicines for Alzheimer Disease Treatment Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Medicines for Alzheimer Disease Treatment Major Company Production Sites & Headquarters
3.6 Global Medicines for Alzheimer Disease Treatment Company, Product Type & Application
3.7 Global Medicines for Alzheimer Disease Treatment Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Medicines for Alzheimer Disease Treatment Market CR5 and HHI
3.8.2 Global Top 5 and 10 Medicines for Alzheimer Disease Treatment Players Market Share by Revenue in 2024
3.8.3 2023 Medicines for Alzheimer Disease Treatment Tier 1, Tier 2, and Tier 3
4 Medicines for Alzheimer Disease Treatment Regional Status and Outlook
4.1 Global Medicines for Alzheimer Disease Treatment Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Medicines for Alzheimer Disease Treatment Historic Market Size by Region
4.2.1 Global Medicines for Alzheimer Disease Treatment Sales in Volume by Region (2020-2025)
4.2.2 Global Medicines for Alzheimer Disease Treatment Sales in Value by Region (2020-2025)
4.2.3 Global Medicines for Alzheimer Disease Treatment Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Medicines for Alzheimer Disease Treatment Forecasted Market Size by Region
4.3.1 Global Medicines for Alzheimer Disease Treatment Sales in Volume by Region (2026-2031)
4.3.2 Global Medicines for Alzheimer Disease Treatment Sales in Value by Region (2026-2031)
4.3.3 Global Medicines for Alzheimer Disease Treatment Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Medicines for Alzheimer Disease Treatment by Application
5.1 Medicines for Alzheimer Disease Treatment Market by Application
5.1.1 Hospital Pharmacy
5.1.2 Online Pharmacy
5.1.3 Retail Pharmacy
5.2 Global Medicines for Alzheimer Disease Treatment Market Size by Application
5.2.1 Global Medicines for Alzheimer Disease Treatment Market Size Overview by Application (2020-2031)
5.2.2 Global Medicines for Alzheimer Disease Treatment Historic Market Size Review by Application (2020-2025)
5.2.3 Global Medicines for Alzheimer Disease Treatment Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Medicines for Alzheimer Disease Treatment Sales Breakdown by Application (2020-2025)
5.3.2 Europe Medicines for Alzheimer Disease Treatment Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Medicines for Alzheimer Disease Treatment Sales Breakdown by Application (2020-2025)
5.3.4 South America Medicines for Alzheimer Disease Treatment Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Medicines for Alzheimer Disease Treatment Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Novartis AG
6.1.1 Novartis AG Comapny Information
6.1.2 Novartis AG Business Overview
6.1.3 Novartis AG Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novartis AG Medicines for Alzheimer Disease Treatment Product Portfolio
6.1.5 Novartis AG Recent Developments
6.2 AbbVie Inc
6.2.1 AbbVie Inc Comapny Information
6.2.2 AbbVie Inc Business Overview
6.2.3 AbbVie Inc Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.2.4 AbbVie Inc Medicines for Alzheimer Disease Treatment Product Portfolio
6.2.5 AbbVie Inc Recent Developments
6.3 Lupin Pharmaceuticals, Inc
6.3.1 Lupin Pharmaceuticals, Inc Comapny Information
6.3.2 Lupin Pharmaceuticals, Inc Business Overview
6.3.3 Lupin Pharmaceuticals, Inc Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Lupin Pharmaceuticals, Inc Medicines for Alzheimer Disease Treatment Product Portfolio
6.3.5 Lupin Pharmaceuticals, Inc Recent Developments
6.4 Janssen Global Services, LLC
6.4.1 Janssen Global Services, LLC Comapny Information
6.4.2 Janssen Global Services, LLC Business Overview
6.4.3 Janssen Global Services, LLC Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Janssen Global Services, LLC Medicines for Alzheimer Disease Treatment Product Portfolio
6.4.5 Janssen Global Services, LLC Recent Developments
6.5 H. Lundbeck A/S
6.5.1 H. Lundbeck A/S Comapny Information
6.5.2 H. Lundbeck A/S Business Overview
6.5.3 H. Lundbeck A/S Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.5.4 H. Lundbeck A/S Medicines for Alzheimer Disease Treatment Product Portfolio
6.5.5 H. Lundbeck A/S Recent Developments
6.6 F. Hoffmann-La Roche Ltd
6.6.1 F. Hoffmann-La Roche Ltd Comapny Information
6.6.2 F. Hoffmann-La Roche Ltd Business Overview
6.6.3 F. Hoffmann-La Roche Ltd Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.6.4 F. Hoffmann-La Roche Ltd Medicines for Alzheimer Disease Treatment Product Portfolio
6.6.5 F. Hoffmann-La Roche Ltd Recent Developments
6.7 Daiichi Sankyo Company Limited
6.7.1 Daiichi Sankyo Company Limited Comapny Information
6.7.2 Daiichi Sankyo Company Limited Business Overview
6.7.3 Daiichi Sankyo Company Limited Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Daiichi Sankyo Company Limited Medicines for Alzheimer Disease Treatment Product Portfolio
6.7.5 Daiichi Sankyo Company Limited Recent Developments
6.8 Amneal Pharmaceuticals LLC
6.8.1 Amneal Pharmaceuticals LLC Comapny Information
6.8.2 Amneal Pharmaceuticals LLC Business Overview
6.8.3 Amneal Pharmaceuticals LLC Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Amneal Pharmaceuticals LLC Medicines for Alzheimer Disease Treatment Product Portfolio
6.8.5 Amneal Pharmaceuticals LLC Recent Developments
6.9 Actiza Pharmaceutical Private Limited
6.9.1 Actiza Pharmaceutical Private Limited Comapny Information
6.9.2 Actiza Pharmaceutical Private Limited Business Overview
6.9.3 Actiza Pharmaceutical Private Limited Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Actiza Pharmaceutical Private Limited Medicines for Alzheimer Disease Treatment Product Portfolio
6.9.5 Actiza Pharmaceutical Private Limited Recent Developments
6.10 AC Immune
6.10.1 AC Immune Comapny Information
6.10.2 AC Immune Business Overview
6.10.3 AC Immune Medicines for Alzheimer Disease Treatment Sales, Revenue and Gross Margin (2020-2025)
6.10.4 AC Immune Medicines for Alzheimer Disease Treatment Product Portfolio
6.10.5 AC Immune Recent Developments
7 North America by Country
7.1 North America Medicines for Alzheimer Disease Treatment Sales by Country
7.1.1 North America Medicines for Alzheimer Disease Treatment Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Medicines for Alzheimer Disease Treatment Sales by Country (2020-2025)
7.1.3 North America Medicines for Alzheimer Disease Treatment Sales Forecast by Country (2026-2031)
7.2 North America Medicines for Alzheimer Disease Treatment Market Size by Country
7.2.1 North America Medicines for Alzheimer Disease Treatment Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Medicines for Alzheimer Disease Treatment Market Size by Country (2020-2025)
7.2.3 North America Medicines for Alzheimer Disease Treatment Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Medicines for Alzheimer Disease Treatment Sales by Country
8.1.1 Europe Medicines for Alzheimer Disease Treatment Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Medicines for Alzheimer Disease Treatment Sales by Country (2020-2025)
8.1.3 Europe Medicines for Alzheimer Disease Treatment Sales Forecast by Country (2026-2031)
8.2 Europe Medicines for Alzheimer Disease Treatment Market Size by Country
8.2.1 Europe Medicines for Alzheimer Disease Treatment Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Medicines for Alzheimer Disease Treatment Market Size by Country (2020-2025)
8.2.3 Europe Medicines for Alzheimer Disease Treatment Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Medicines for Alzheimer Disease Treatment Sales by Country
9.1.1 Asia-Pacific Medicines for Alzheimer Disease Treatment Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Medicines for Alzheimer Disease Treatment Sales by Country (2020-2025)
9.1.3 Asia-Pacific Medicines for Alzheimer Disease Treatment Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Medicines for Alzheimer Disease Treatment Market Size by Country
9.2.1 Asia-Pacific Medicines for Alzheimer Disease Treatment Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Medicines for Alzheimer Disease Treatment Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Medicines for Alzheimer Disease Treatment Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Medicines for Alzheimer Disease Treatment Sales by Country
10.1.1 South America Medicines for Alzheimer Disease Treatment Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Medicines for Alzheimer Disease Treatment Sales by Country (2020-2025)
10.1.3 South America Medicines for Alzheimer Disease Treatment Sales Forecast by Country (2026-2031)
10.2 South America Medicines for Alzheimer Disease Treatment Market Size by Country
10.2.1 South America Medicines for Alzheimer Disease Treatment Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Medicines for Alzheimer Disease Treatment Market Size by Country (2020-2025)
10.2.3 South America Medicines for Alzheimer Disease Treatment Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Medicines for Alzheimer Disease Treatment Sales by Country
11.1.1 Middle East and Africa Medicines for Alzheimer Disease Treatment Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Medicines for Alzheimer Disease Treatment Sales by Country (2020-2025)
11.1.3 Middle East and Africa Medicines for Alzheimer Disease Treatment Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Medicines for Alzheimer Disease Treatment Market Size by Country
11.2.1 Middle East and Africa Medicines for Alzheimer Disease Treatment Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Medicines for Alzheimer Disease Treatment Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Medicines for Alzheimer Disease Treatment Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Medicines for Alzheimer Disease Treatment Value Chain Analysis
12.1.1 Medicines for Alzheimer Disease Treatment Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Medicines for Alzheimer Disease Treatment Production Mode & Process
12.2 Medicines for Alzheimer Disease Treatment Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Medicines for Alzheimer Disease Treatment Distributors
12.2.3 Medicines for Alzheimer Disease Treatment Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.